Literature DB >> 20658440

Acromegaly: a cross-sectional analysis of the oral and maxillofacial pathologies.

B L Herrmann1, F Mortsch, C Berg, T Weischer, C Mohr, K Mann.   

Abstract

CONTEXT: It is well established that clinical features of acromegaly concern the teeth and the jaw, but less is known about the degree of oral and maxillofacial pathologies. PATIENTS: 28 acromegalics (13 females, 15 males) with a mean age 49±11 (mean±SD) years (range 31-70) were included in the study. 32% had active disease, 68% were well-controlled under the somatostatin analogue octreotide, the dopamine agonist cabergoline, and the GH receptor antagonist pegvisomant, or were cured after pituitary surgery and/or radiation.
METHODS: All subjects undergone intensive and complex examinations of a plaster model and facial arch with articulator, an intra-oral bracket-pen registration, analysis of a digital picture, panoramic and lateral radiographs with cephalometry in comparison with a reference group (n=201).
RESULTS: 42% had a diastema mediale (0.9±1.1 mm). Overbite and overjet (vertical overbite) correlated with the disease duration (r²=0.2237; p=0.011 respectively r²=0.3364; p=0.015). 96% had an asymmetric movement of the mandible. 57% had a prognathism. The protrusion of the mandible correlated significantly with the disease duration (r²=0.1784; p=0.028). The degree of the mandibular prognathism (SNB-angle) was higher in the acromegalic group (84°±7° vs. 81°±3°, p<0.05). The ANB-angle indicates the relation between maxilla and mandible and was negative in the acromegalic group and positive in the controls (-0.3°±5.0° vs. 1.6°±2.1°, p=<0.05) and correlated negative with the disease duration (r²=0.2553; p=0.0061). The mandibular angle was significantly greater in the acromegalic group (126°±9° acromegalic group vs. 121°±7°control group, p=0.003). The length of the mandible correlated with the disease duration (r²=0.2801; p=0.0038). 86% had an asymmetric face. The high of the midface was in the acromegalic group higher (6.1±0.7 vs. 5.5±0.4 cm, p=0.0009) as well as the lower bony high of the face (9.5±1.0 acromegalics vs. 6.9±0.5 cm controls, p=0.0009). The high of the lower bony face correlated with as well with the disease duration (r²=0.3224; p=0.0016).
CONCLUSIONS: Patients with acromegaly suffer not only from cardiovascular, metabolic and neoplastic complications, but also from dental and jaw disorders. The high incidence of these manifestations and its relation to the disease duration requires a carefully work-up of oral and maxillofacial examinations in close collaboration with endocrinologists, dentists and dental surgeons. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2010        PMID: 20658440     DOI: 10.1055/s-0030-1255020

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  10 in total

1.  Three-dimensional facial analysis in acromegaly: a novel tool to quantify craniofacial characteristics after long-term remission.

Authors:  M A E M Wagenmakers; S H P P Roerink; T J J Maal; R H Pelleboer; J W A Smit; A R M M Hermus; S J Bergé; R T Netea-Maier; T Xi
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

2.  Oro-dental pathologies in acromegaly.

Authors:  Ilonka Kreitschmann-Andermahr; Johannes Kohlmann; Bernadette Kleist; Ursula Hirschfelder; Rolf Buslei; Michael Buchfelder; Sonja Siegel
Journal:  Endocrine       Date:  2018-03-08       Impact factor: 3.633

3.  Anatomical features of skull base and oral cavity: a pilot study to determine the accessibility of the sella by transoral robotic-assisted surgery.

Authors:  Aymeric Amelot; Stephanie Trunet; Vincent Degos; Olivier André; Aurore Dionnet; Philippe Cornu; Stéphane Hans; Dorian Chauvet
Journal:  Neurosurg Rev       Date:  2015-05-01       Impact factor: 3.042

4.  The evaluation of changes in maxillofacial bones using cone beam tomography in acromegaly.

Authors:  F Dogruel; E-M Canger; Z-B Gonen; F Asantogrol; A Şahin; F Bayram
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-07-01

5.  Cephalometric features in isolated growth hormone deficiency.

Authors:  Luiz Alves Oliveira-Neto; Mariade de Fátima B Melo; Alexandre A Franco; Alaíde H A Oliveira; Anita H O Souza; Eugênia H O Valença; Isabela M P A Britto; Roberto Salvatori; Manuel H Aguiar-Oliveira
Journal:  Angle Orthod       Date:  2011-02-21       Impact factor: 2.079

6.  Morphological and histopathological changes in orofacial structures of experimentally developed acromegaly-like rats: an overview.

Authors:  Masahiro Iikubo; Ikuho Kojima; Maya Sakamoto; Akane Kobayashi; Hidetoshi Ikeda; Takashi Sasano
Journal:  Int J Endocrinol       Date:  2012-02-28       Impact factor: 3.257

7.  GH-secreting pituitary macroadenoma (acromegaly) associated with progressive dental malocclusion and refractory CPAP treatment.

Authors:  Jaume Miranda-Rius; Lluís Brunet-LLobet; Eduard Lahor-Soler; David de Dios-Miranda; Josep Anton Giménez-Rubio
Journal:  Head Face Med       Date:  2017-05-10       Impact factor: 2.151

Review 8.  Oral Manifestations and Maxillo-Facial Features in the Acromegalic Patient: A Literature Review.

Authors:  Alberto De Stefani; Francesca Dassie; Alexandra Wennberg; Giorgia Preo; Alice Muneratto; Roberto Fabris; Pietro Maffei; Antonio Gracco; Giovanni Bruno
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

9.  The role of the dentist and orthodontist in recognizing oro-facial manifestations of acromegaly: a questionnaire-based study.

Authors:  Giorgia Preo; Alberto De Stefani; Francesca Dassie; Alexandra Wennberg; Roberto Vettor; Pietro Maffei; Antonio Gracco; Giovanni Bruno
Journal:  Pituitary       Date:  2021-09-13       Impact factor: 4.107

10.  Assessment of oro-dental manifestations in a series of acromegalic patients, the AcroDent study.

Authors:  Sylvain Roumeau; Joannice Thevenon; Lemlih Ouchchane; Salwan Maqdasy; Marie Batisse-Lignier; Christian Duale; Nathalie Pham Dang; Philippe Caron; Igor Tauveron; Laurent Devoize
Journal:  Endocr Connect       Date:  2020-08       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.